Glenn P. Sblendorio, M.B.A.
President and Chief Executive Officer
David F. Carroll, M.B.A.
Chief Financial Officer
Mr. Carroll is a certified public accountant and received a BA from Ursinus College magna cum laude and an MBA from Rutgers University.
Evelyn Harrison, M.B.A.
Chief Clinical Operations Officer
Prior to joining Ophthotech, Ms. Harrison was with Eyetech Pharmaceuticals, Inc., where she held the management positions of Vice President and Senior Vice President of Clinical Research and Development. While at Eyetech, Ms. Harrison, played a key role in the development and approval of Macugen® (pegaptanib sodium) for the treatment of wet age-related macular degeneration.
Ms. Harrison’s professional career began in clinical research at a major New York City teaching hospital. She then moved to Hoffmann-La Roche Inc., where she was Director of Clinical Operations, responsible for the development and implementation of strategic programs for Roche’s oncology franchise.
Ms. Harrison has worked on all phases of global clinical trials and has extensive experience in multiple therapeutic areas such as bone marrow transplantation, organ transplantation, oncology and virology.
Ms. Harrison holds a B.A. degree in Biology from Hofstra University and a Master of Business Administration (M.B.A.) degree from Manhattan College.
Kourous A. Rezaei, M.D.
Senior Vice President, Medical Strategy
Dr. Rezaei received his medical degree from the University of Cologne in Germany. He served as chief resident while completing his residency at the University of Chicago. Dr. Rezaei completed his vitreoretinal surgery fellowship at the Kresge Eye Institute in Detroit.
Senior Vice President, Technical Operations
Keith Westby, M.B.A.
Senior Vice President and Chief Operating Officer
Senior Vice President and General Counsel
Before joining OSI, Ms. Wood was a partner at the New York firm of Squadron, Ellenoff, Plesent & Sheinfeld (now part of Hogan Lovells), focusing on mergers and acquisitions, biotechnology, licensing, securities and venture capital matters. While at Squadron Ellenoff, she also worked on transactions for some of the earliest biotech companies, representing an early biotech venture capitalist and angel investor. Ms. Wood received her law degree from Columbia Law School where she was a Harlan Fiske Stone Scholar and has a Bachelor of Arts (B.A.) degree in Economics and Classics from Connecticut College.